Meng （Amanda） Fu

Meng (Amanda) Fu has extensive work experience in the pharmaceutical and healthcare industry. Meng （Amanda） is currently the Chief Executive Officer at D2V Clinical, a position they have held since September 2019. Prior to that, they worked as the Vice President at 3DMedicines from April 2018 to September 2019. Meng also served as the Senior Clinical Research Lead at MedImmune from September 2015 to April 2018. Meng （Amanda） held the role of President at the Sino-American Pharmaceutical Professionals Association Washington DC/Baltimore from December 2015 to September 2017. Meng has also worked in various roles at Pharmacyclics, INC Research, Complete Healthcare for Women, GE Healthcare, Gleneaglescrc, and Boehringer Ingelheim Pharmaceuticals, demonstrating their expertise in project management, clinical research, and leadership. Meng （Amanda）'sexperience spans from 2004 to the present, showcasing their long-standing commitment to the industry.

Meng Fu, also known as Amanda Fu, has a comprehensive education history in various fields. Starting in 1996, they attended Jilin University where they pursued a Doctor of Medicine (M.D.) degree in Medicine, which they completed in 2001. Following this, they undertook a one-year Medical Internship at Beijing Electric Power General Hospital from 2001 to 2002. In 2002, they enrolled in The University of Sheffield and obtained a Master's degree in Evidence Based Medicine between 2002 and 2004. Lastly, in 2011, Meng Fu pursued a Master of Business Administration (M.B.A.) degree at Ohio University, which they successfully completed in 2013. Throughout their education, Meng Fu has acquired expertise in medicine, evidence-based research, and business administration.